SCHOTT PHARMA AG & CO KGAA
Commented by Jens Castner on October 30th, 2026 | 05:45 CET
When the stock market gets it wrong: Schott Pharma clears its name; Lahontan Gold and Instone are the next candidates
Markets are quick to judge, and often paint companies with a broad brush. When one company runs into difficulties, its competitors immediately come under suspicion too. Schott Pharma has already been through this and dispelled the doubts with strong figures. Its share price is recovering. For Lahontan Gold and Instone Real Estate, the recovery has yet to come. The Canadian gold explorer is being punished alongside the major producers, while the property developer is being grouped with Berlin's residential landlords. In both cases, the facts tell a different story. The share price upside is considerable.
Read
Commented by Carsten Mainitz on February 12th, 2026 | 07:55 CET
Watch out! Gerresheimer slumps 30%, NEO Battery Materials as a game changer, Schott Pharma surprises positively
Many stories of success and failure are written on the stock market. NEO Battery Materials, the game changer in battery technology, is particularly exciting. The Canadian company offers manufacturers of drones, robots, and electric vehicles customizable high-performance batteries produced in the West. With its innovative approach, the company is setting new standards in terms of performance, charging speed, and price, thereby addressing a huge market that experts estimate will grow to around USD 30 billion by 2032. The examples of Gerresheimer and Schott Pharma show how differently companies in the same industry can develop: Schott exceeded market expectations in the first quarter, while Gerresheimer shocked the markets once again.
Read
Commented by Nico Popp on September 27th, 2023 | 07:10 CEST
Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics
High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!
Read